Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 391231140
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.50 | 13.80 | -0.15% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,763.85 | 212.94 | -0.82% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 49,994.30 | 842.25 | -1.66% |
| NZX 50 Index | 13,399.20 | 7.71 | -0.06% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,628.60 | 15.30 | -0.18% |
| SSE Composite Index | 3,884.93 | 4.41 | -0.11% |